Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer

Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer

An indirect consequence of the improved long-term survival seen in patients with breast cancer (BC) is the increased risk of hematologic malignant neoplasms (HM). This study aimed to analyze the role of postoperative treatment for BC in the development of subsequent HM. Using the French National Hea...

Full description

Bibliographic Details
Main Authors:	Marie Joelle Jabagi, Anthony Goncalves, Norbert Vey, Thien Le Tri, Mahmoud Zureik, Rosemary Dray-Spira
Format:	Article
Language:	English
Published:	MDPI AG 2019-09-01
Series:	Cancers
Subjects:	breast cancer secondary hematologic malignant neoplasms secondary cancers leukemia lymphoma treatment-related complications chemotherapy radiotherapy hormonal therapy epidemiology
Online Access:	https://www.mdpi.com/2072-6694/11/10/1463

Similar Items

Secondary hematological malignancies following breast cancer treatment
by: Soley Bayraktar, et al.
Published: (2011-12-01)

Pattern of hematological malignancy in a tertiary level hospital in Kathmandu
by: Amar Narayan Shrestha, et al.
Published: (2019-03-01)

Radioprotective Agents and Enhancers Factors. Preventive and Therapeutic Strategies for Oxidative Induced Radiotherapy Damages in Hematological Malignancies
by: Andrea Gaetano Allegra, et al.
Published: (2020-11-01)

Hematologic malignancies during preg
by: Hossam K. Mahmoud, et al.
Published: (2016-07-01)

CAR T-Cell Therapy in Hematological Malignancies
by: Theresa Haslauer, et al.
Published: (2021-08-01)

Epigenetic Effects of Benzene in Hematologic Neoplasms: The Altered Gene Expression
by: Giovanna Spatari, et al.
Published: (2021-05-01)

Deubiquitinases in hematological malignancies
by: Hu Lei, et al.
Published: (2021-08-01)

SECONDARY ACUTE PROMYELOCYTIC LEUKEMIA DEVELOPED AFTER TREATMENT OF NON-HODGKIN'S LYMPHOMA. CLINICAL CASE AND REVIEW OF LITERATURE.
by: Victor Tomacinschii, et al.
Published: (2020-10-01)

Prospective study of strongyloidosis in patients with hematologic malignancies
by: Graeff-Teixeira Carlos, et al.
Published: (1997-01-01)

Steering Mast Cells or Their Mediators as a Prospective Novel Therapeutic Approach for the Treatment of Hematological Malignancies
by: Deeksha Mehtani, et al.
Published: (2021-09-01)

The DNA methylation landscape of hematological malignancies: an update
by: Pedro Blecua, et al.
Published: (2020-08-01)

Risk factors of hematological malignancies in Upper Egypt: a case–control study
by: Safinaz Hussein, et al.
Published: (2019-01-01)

Effect of Akimbo Versus Raised Arm Positioning on Breast and Cardiopulmonary Dosimetry in Pediatric Hodgkin Lymphoma
by: Kyle Denniston, et al.
Published: (2016-07-01)

From the (Epi)Genome to Metabolism and Vice Versa; Examples from Hematologic Malignancy
by: Panagiota Karagianni, et al.
Published: (2021-06-01)

Crosstalk Between MYC and lncRNAs in Hematological Malignancies
by: Kaifee Arman, et al.
Published: (2020-10-01)

Interpreting Outcome Data in Hematological Malignancies: A Paradigm for Clinical Studies
by: Jacob M. Rowe
Published: (2013-01-01)

Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies
by: Natasha Irrera, et al.
Published: (2021-06-01)

Long-term maintenance of eosinophilic dermatosis of hematologic malignancy with doxycycline
by: Karolina Mieczkowska, BS, et al.
Published: (2021-10-01)

Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned
by: Alessandro Isidori, et al.
Published: (2020-08-01)

New Insights into YES-Associated Protein Signaling Pathways in Hematological Malignancies: Diagnostic and Therapeutic Challenges
by: Alessandro Allegra, et al.
Published: (2021-04-01)

Secondary Malignancy Risk Following Proton vs. X-ray Treatment of Mediastinal Malignant Lymphoma: A Comparative Modeling Study of Thoracic Organ-Specific Cancer Risk
by: Laila König, et al.
Published: (2020-07-01)

Association of high mobility group BOX-1 and receptor for advanced glycation endproducts with clinicopathological features of haematological malignancies: a systematic review
by: Austin H. Nguyen, et al.
Published: (2017-01-01)

Risk of hematological malignancies in the families of patients treated for nodular lymphocyte-predominant Hodgkin lymphoma
by: Saad Akhtar, et al.
Published: (2021-02-01)

Clinical Value of ctDNA in Hematological Malignancies (Lymphomas, Multiple Myeloma, Myelodysplastic Syndrome, and Leukemia): A Meta-Analysis
by: Xiangyu Tan, et al.
Published: (2021-03-01)

A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017
by: Mohammad Keykhaei, et al.
Published: (2021-02-01)

Evaluation of Sexual Dysfunction in Patients with Hematological Malignancies
by: Yasemin Karacan, et al.
Published: (2021-01-01)

Hematological malignancies in relation with ABO blood group at a teaching hospital, Varanasi, India
by: Sandip Kumar, et al.
Published: (2020-01-01)

Myeloid-derived suppressor cells in hematological malignancies: friends or foes
by: Meng Lv, et al.
Published: (2019-10-01)

Clinicoepidemiological profile of hematological malignancies in pediatric age group in Ahmedabad
by: Zankhana Prajapati, et al.
Published: (2017-01-01)

Unmet Supportive Care Needs of Patients with Hematological Malignancies: A Systematic Review
by: Ioanna Tsatsou, et al.
Published: (2021-01-01)

Recent advances in radiotherapy and its associated side effects in cancer—a review
by: Gomathi Mohan, et al.
Published: (2019-02-01)

Hematological Malignancy-Derived Small Extracellular Vesicles and Tumor Microenvironment: The Art of Turning Foes into Friends
by: Ernesto Gargiulo, et al.
Published: (2019-05-01)

A case of chronic lymphocytic leukemia with massive ascites
by: Meliha Nalcaci, et al.
Published: (2012-10-01)

Monitoring of patients with hematological malignancies after anticancer therapy
by: A. E. Rudneva, et al.
Published: (2015-01-01)

Monitoring of patients with hematological malignancies after anticancer therapy
by: A. E. Rudneva, et al.
Published: (2015-01-01)

B-cell acute lymphoblastic leukemia as a secondary malignancy following diffuse large B-cell lymphoma
by: Daria Gaut, et al.
Published: (2019-06-01)

Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
by: Jun Meng, et al.
Published: (2021-07-01)

Role of quantitative diffusion-weighted imaging in differentiation between red and infiltrated marrow in pediatric patients with hematologic malignancy
by: Yosra Abdelzaher Ibrahim, et al.
Published: (2019-09-01)

Corrigendum: Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis
by: Jun Meng, et al.
Published: (2021-10-01)

Altered leukogram and hematological parameters among leukemia patients
by: Andrew Nuhu Yashim, et al.
Published: (2021-01-01)